De Blasio MJ, Lanham SA, Blache D, Oreffo RO, Fowden AL, Forhead AJ. Sex-and bone-specific responses in bone structure to exogenous leptin and leptin receptor antagonism in the ovine fetus. Am spread expression of leptin and its receptor in developing cartilage and bone suggests that leptin may regulate bone growth and development in the fetus. Using microcomputed tomography, this study investigated the effects of exogenous leptin and leptin receptor antagonism on aspects of bone structure in the sheep fetus during late gestation. From 125 to 130 days of gestation (term~145 days), chronically catheterized singleton sheep fetuses were infused intravenously for 5 days with either saline (0.9% saline, n ϭ 13), recombinant ovine leptin at two doses (0.6 mg·kg Ϫ1 ·day Ϫ1 LEP1, n ϭ 10 or 1.4 mg·kg Ϫ1 ·day Ϫ1 LEP2, n ϭ 7), or recombinant superactive ovine leptin receptor antagonist (4.6 mg·kg Ϫ1 ·day Ϫ1 SOLA, n ϭ 6). No significant differences in plasma insulin-like growth factor-I, osteocalcin, calcium, inorganic phosphate, or alkaline phosphatase were observed between treatment groups. Total femur midshaft diameter and metatarsal lumen diameter were narrower in male fetuses treated with exogenous leptin. In a fixed length of femur midshaft, total and bone volumes were reduced by the higher dose of leptin; nonbone space volume was lower in both groups of leptin-treated fetuses. Leptin infusion caused increments in femur porosity and connectivity density, and vertebral trabecular thickness. Leptin receptor antagonism decreased trabecular spacing and increased trabecular number, degree of anisotrophy, and connectivity density in the lumbar vertebrae. The increase in vertebral porosity observed following leptin receptor antagonism was greater in the malecompared with female, fetuses. Therefore, leptin may have a role in the growth and development of the fetal skeleton, dependent on the concentration of leptin, sex of the fetus, and bone type examined. femur; metatarsal; vertebra
INTRODUCTION
Leptin is a hormone primarily secreted by white adipose tissue that was first identified as an important regulator of appetite and energy expenditure (50) and, in adult life, is now known to have a wide range of biological actions, including modulation of immune, neuroendocrine, and reproductive function and bone metabolism (37, 47) . Before birth, the expression of leptin and its receptors is widespread in fetal and placental tissues, although, to date, the role of leptin in the control of growth and development in utero is poorly understood (14) . In the mouse fetus, mRNA and protein for leptin and its long-form signaling receptor, Ob-Rb, have been localized in particular to the skeleton, including vertebrae, ribs, and the bones of the fore-and hindlimbs (7, 23, 24) . Leptin and its receptor were expressed in different cell types in the rib of the murine fetus, indicating that leptin may exert paracrine and endocrine actions in the developing cartilage-bone (23) .
In human fetuses sampled by cordocentesis at 18 -35 wk of gestation, a negative correlation has been observed between plasma leptin and a marker of bone resorption (cross-linked carboxy-terminal telopeptode of type I collagen; see Ref. 36) . Leptin may, therefore, inhibit bone resorption to promote growth of the fetal skeleton. Indeed, at birth, umbilical leptin concentration has been shown to correlate positively with whole body bone mineral content and estimated bone density in human neonates (27) . However, in a study examining umbilical samples from large, small, and average-sized babies, plasma leptin did not relate to whole body bone mineral density or content determined within the first 24 h of life (1) . In addition, there are conflicting reports detailing changes in bone density in infants born to diabetic mothers who are exposed to high concentrations of leptin in utero (18, 29, 42) .
A variety of experimental studies in vivo and in vitro have demonstrated that the actions of leptin on bone growth and development in postnatal animals are complex and depend on factors, including 1) the leptin dose, 2) route of administration, 3) age of the animal, and 4) the skeletal region and type of bone tissue examined (30) . In prepubertal mice, the epiphyseal growth plate has been shown to express Ob-Rb, and leptin treatment increases the size of the tibial growth plate in association with proliferation and differentiation of chondrocytes (16) . Leptin receptors are also present in isolated fetal rat osteoblasts and in primary cultures of adult osteoblasts and chondrocytes (9, 43) . Studies in vitro have shown that leptin directly stimulates proliferation and differentiation of osteoblasts while inhibiting differentiation of bone adipocytes (9, 45) . In contrast, it has also been reported in rodents and sheep that leptin can suppress bone formation indirectly by hypothalamic control of sympathetic and cocaine amphetamine-regulated transcript (CART) pathways (12, 13, 39, 49) . Both hypothalamic and peripheral administration of leptin have been shown to correct the skeletal abnormalities seen in leptindeficient ob/ob mice, in association with elevated serum insulin-like growth factor-I (IGF-I) and osteocalcin levels, a marker of osteoblast activity (2, 26, 46) . The overall effect of leptin on bone development, therefore, may depend on the balance between peripheral and central leptin signaling pathways although the relative importance of these mechanisms in bone remodeling remains controversial (30) .
The role of leptin in the control of bone growth and development before birth is unclear. Previous studies have shown that plasma leptin concentration is elevated in hypothyroid fetal sheep that show abnormalities in bone growth and development (22, 28) although the extent to which leptin contributes to the bone phenotype in this model remains unknown. The present study investigated the effects of leptin treatment and leptin receptor antagonism on plasma IGF-I and osteocalcin concentrations, and aspects of bone structure determined by microcomputed tomography, in the sheep fetus during late gestation. The study hypothesized that exogenous leptin treatment would promote, while antagonism of the leptin receptor would inhibit, the normal development of bone, and plasma IGF-I and osteocalcin concentrations, in the sheep fetus.
METHODS

Animals
All surgical and experimental procedures were approved by the local animal ethics committee and were carried out in accordance with the United Kingdom Animals (Scientific Procedures) Act of 1986 under Home Office project license PPL70/7645. Thirty-six Welsh Mountain sheep with singleton pregnancies of known gestational age were used in this study. The pregnant ewes were housed in individual pens and maintained on 200 g/kg concentrates with free access to hay, water, and a salt-lick block.
Surgical Procedures
The pregnant ewes were fasted for 18 -24 h before surgery with free access to water. At between 118 and 120 days of pregnancy (term 145 Ϯ 2 days) and under general anesthesia (1.5% halothane in O 2-N2O), catheters were inserted in the femoral artery and vein of the fetus and the femoral artery of the ewe using techniques previously described (8) . All catheters were exteriorized through the flank of the ewe and secured in a bag sutured to the skin. The vascular catheters were flushed daily with heparinized saline solution (100 IU heparin in 0.9% saline) from the day after surgery. At surgery, all fetuses were administered intravenously with 100 mg ampicillin (Penbritin; Beecham Animal Health, Brentford, UK) and 2 mg gentamycin (Frangen-100; Biovet, Mullingar, Ireland). Ewes were administered with antibiotics intramuscularly (Depocillin; Mycofarm, Cambridge, UK) on the day of surgery and for 3 days thereafter.
Experimental Procedures
Starting at 125 days of gestation and for a period of 5 days, one group of fetuses was infused intravenously with saline (0.9% sodium chloride, n ϭ 13) while a further three groups received either recombinant ovine leptin (LEP) at two doses (0.56 Ϯ 0.02 mg·kg Ϫ1 ·day Ϫ1 LEP1, n ϭ 10 or 1.35 Ϯ 0.11 mg·kg Ϫ1 ·day Ϫ1 LEP2, n ϭ 7) or recombinant superactive ovine leptin antagonist (SOLA) (4.56 Ϯ 0.24 mg·kg Ϫ1 ·day Ϫ1 SOLA, n ϭ 6; Protein Laboratories, Rehovot, Israel; see Refs. 17 and 34) . The doses of leptin administered increased circulating leptin to supraphysiological concentrations in the sheep fetus (10) and by a similar magnitude as that seen in the umbilical blood of babies born to women with obesity and/or diabetes during pregnancy (6, 18) . The leptin antagonist was produced by D23L/ L39A/D40A/F41A mutation of recombinant ovine leptin (34) . The leptin mutant competes with endogenous leptin for binding sites on all forms of the leptin receptor but lacks biological activity (34) . In fetal sheep, a less potent form of the recombinant ovine leptin receptor antagonist (mutant L39A/D40A/FA1A/I42A, OLA) at a dose of 1.5 mg·kg Ϫ1 ·day Ϫ1 iv has previously been shown to reduce STAT-3 phosphorylation by~50% in the adrenal cortex (11) . The treatments were administered via the fetal venous catheter at a rate of 3 ml/day using a Graseby portable infusion pump. Arterial blood from the fetus and ewe (3 ml) was collected daily from 2 days before and during the 5-day infusion period.
On the fifth day of infusion at 130 days of gestation, the fetuses were delivered by caesarean section under maternal general anesthesia (20 mg/kg iv pentobarbital sodium). After administration of a lethal dose of barbiturate (200 mg/kg iv pentobarbital sodium) to the ewe and fetus, the fetus was weighed, and a variety of tissues were collected. In all fetuses, body weight, crown-rump length, and forelimb (humerus, radius, and metacarpus) and hindlimb (femur, tibia, and metatarsal) lengths were measured. Three selected bones from the axial and appendicular skeleton (femur, metatarsal, and lumbar vertebra L 2-L4) were dissected and frozen at Ϫ80°C.
Biochemical Analyses
All blood samples were collected in EDTA-containing tubes and centrifuged at 1,000 g for 5 min at 4°C; the plasma was stored at Ϫ20°C until analysis. Plasma concentrations of leptin and IGF-I were determined by RIA as previously described (4, 15) . The intra-assay coefficients of variation were 4 -5%, and the minimum levels of detection were 0.09 and 0.08 ng/ml, respectively. Plasma osteocalcin concentrations were determined using an ELISA kit (Immunodiagnostics Systems, Boldon, UK); the intra-assay coefficient of variation was 4%, and the lower limit of assay detection was 0.5 ng/ml. Total plasma calcium, inorganic phosphate, and alkaline phosphatase concentrations were measured using a Siemens Dimension RXL-2 autoanalyzer (Siemens Healthcare, Camberley, UK). The minimum levels of detection were 1.25 mM, 0.1 mM, and 11 U/l, respectively.
Microcomputed Tomography
The femur and metatarsal and lumbar vertebrae were scanned using a Skyscan 1176 in vivo micro-CT scanner (Bruker micro-CT, Kontich, Belgium). All scans were taken at 50 kV and 50 A with a 0.5-mm aluminium filter and 0.4°rotation step. Individual 2-dimensional cross-sectional images were reconstructed using Bruker NRecon software version 1.6.5.8. Voxel resolution was 18 m. Reconstructed images were analyzed using Bruker CTAn software version 1.13.5.1 to calculate bone volume, bone volume-to-total volume ratio, bone surface-to-bone volume ratio, and trabecular thickness, number, and spacing. In addition, measurements were made of trabecular pattern factor (relative convex or concave nature of the total bone surface), porosity, connectivity density, structural model index (SMI, surface convexity), and degree of anisotropy (DOA, orientation of trabeculas). In the femur and metatarsal, a 3.56-mm length of midshaft bone was assessed for volumes of lumen, bone tissue, and space between the bone tissue.
Statistical Analysis
All data were tested for normality, and parametric and nonparametric tests were used as appropriate (SPSS Statistics 20 statistical analysis software). Values obtained from the four groups were compared separately to assess the effects of leptin infusion (saline, LEP1, LEP2) and the effects of leptin receptor antagonism (saline, SOLA). Initially, all data were analyzed by two-way ANOVA, with treatment and sex of the fetus as factors, followed by Tukey's post hoc test. Where data were not influenced by the sex of the fetus, one-way ANOVA followed by Tukey's post hoc test, or paired or Student's unpaired t-test as appropriate, was used to assess the effects of treatment. Differences where P Ͻ 0.05 were regarded as significant. All data are presented as mean Ϯ SE values.
RESULTS
Plasma Hormone and Metabolite Concentrations
Plasma leptin concentrations in the fetuses treated with recombinant ovine leptin increased significantly over the period of the infusion (P Ͻ 0.05, Table 1 ). The RIA method used to measure plasma leptin detected the recombinant ovine leptin receptor antagonist as leptin; therefore, the apparent plasma leptin concentrations in the fetuses infused with the antagonist were also increased from pretreatment levels (P Ͻ 0.05, Table 1 ). On the fifth day of treatment, plasma leptin concentrations in the fetuses infused with either leptin or leptin receptor antagonist were significantly higher than those observed in the control fetuses infused with saline; values were increased by leptin infusion in a dose-dependent manner (P Ͻ 0.05, Table 1 ).
Plasma concentrations of IGF-I, osteocalcin, calcium, and inorganic phosphate did not differ between the treatment groups before or after infusion and were unaffected by administration of leptin or leptin receptor antagonist over 5 days (Table 1 ). Plasma alkaline phosphatase concentrations were increased by gestational age over the 5 days of treatment in all groups of fetuses (P Ͻ 0.05, Table 1 ). There was no difference in the change in plasma alkaline phosphatase observed over the period of study between the treatment groups ( Table 1) .
Body Morphometry
No significant differences in fetal body weight, crown-rump length, or limb lengths were observed between the treatment Values are means Ϯ SE; n, no. of fetuses. Shown are plasma hormone and metabolite concentrations in the fetuses before (basal) and 5 days after infusion with saline, leptin (LEP1, LEP2), or leptin receptor antagonist (SOLA). Basal, mean of days 0, Ϫ1, and Ϫ2. In comparisons between saline and leptin treatment groups, values with different superscript letters are significantly different from each other (1-way ANOVA, P Ͻ 0.05). †Significant difference between fetuses treated with saline or leptin receptor antagonist (Student's unpaired t-test, P Ͻ 0.05). *Significant difference from basal values (paired t-test, P Ͻ 0.05).
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groups at the end of the 5-day infusion period, when measurements were made before dissection ( Table 2) . When data from the fetuses treated with saline or the leptin receptor antagonist were assessed, a significant effect of sex was identified for the metatarsal, radius, and metacarpal bone lengths (P Ͻ 0.05 in all cases); however, although the data indicated that values were greater in the male compared with female fetuses, the results of the Tukey post hoc tests failed to reach significance for each pairwise comparison (P Ͼ 0.05). There were no interactions between sex and treatment for any of the measurements of body weight or limb length.
Bone Structure
Exogenous leptin infusion. Femur midshaft diameter was significantly narrower in the fetuses of the LEP2 group compared with those infused with saline (P Ͻ 0.05, Table 3 ); midshaft diameter in the LEP1 fetuses was intermediate to the values observed in the saline and LEP2 fetuses ( Table 3) .
When analyzed by sex, femur midshaft diameter was significantly greater in the male compared with female fetuses of the saline group alone; midshaft diameter was reduced by leptin infusion in the male, but not female, fetuses of the LEP1 and LEP2 groups (P Ͻ 0.05, Table 3 ).
In a fixed length of femur midshaft bone, total volume was significantly lower in the LEP2-treated fetuses compared with the saline control group, whereas the values in the LEP1treated fetuses were intermediate (P Ͻ 0.05, Fig. 1 ). The midshaft volume composed of nonbone space was significantly decreased by leptin treatment in both LEP1 and LEP2 groups (P Ͻ 0.05, Fig. 1A) . In LEP1-treated fetuses, the nonbone space expressed as a proportion of the total volume was significantly lower than that observed in the saline-treated fetuses (P Ͻ 0.05, Fig. 1B) . A significant reduction in bone tissue volume was seen in the fetuses treated with the higher dose of leptin compared with those treated with the lower dose (P Ͻ 0.05, Fig. 1A) . The bone surface-to-volume ratio in the femur tended to increase with leptin treatment, but this change failed to reach statistical significance (P ϭ 0.08, Table 3 ).
In the saline control group alone, the midshaft lumen diameter of the metatarsal bone was significantly greater in the male than the female fetuses; midshaft lumen diameter was decreased by leptin infusion in male, but not female, fetuses of the LEP1 and LEP2 groups (P Ͻ 0.05, Table 3 ). In the fixed length of midshaft bone, the bone tissue volume was significantly lower in the fetuses treated with the higher dose of leptin compared with those treated with the lower dose (P Ͻ 0.05, Fig. 2A ).
Significant increments in femur trabecular porosity and connectivity density, and vertebral trabecular thickness, were observed in the LEP1-infused fetuses compared with the control saline group (P Ͻ 0.05, Fig. 3) ; these parameters were also elevated in the LEP2 fetuses but failed to differ significantly from the values in the saline control group (Fig. 3) .
For all other parameters measured in the femur and metatarsal and lumbar vertebrae, no significant differences were observed between the fetuses infused with saline or leptin ( Table 3 ). Leptin treatment influenced trabecular thickness (P ϭ 0.07) and DOA (P ϭ 0.08) in the metatarsal, and body length (P ϭ 0.09), bone surface-to-volume ratio (P ϭ 0.08), trabecular pattern factor (P ϭ 0.07), and structural model index (P ϭ 0.08) in the lumbar vertebrae, but these effects failed to reach statistical significance (Table 3) .
Leptin receptor antagonism. In the lumbar vertebra, leptin receptor antagonism caused a significant decrease in trabecular spacing and increases in trabecular number, DOA, and connectivity density (P Ͻ 0.05, Fig. 4 ). Lumbar vertebral porosity was also increased following treatment with the leptin receptor antagonist in a sex-dependent manner, with the increment in porosity greater in the male, compared with the female, fetuses (P Ͻ 0.05, Fig. 5 ).
In the other bones, there were no significant differences in any of the other measured parameters between the fetuses infused with saline or the leptin antagonist (Table 4 ). Measurements of femur midshaft total diameter, metatarsal midshaft total and lumen diameter, vertebral bone surface-to-volume ratio, and structural model index were greater in the male compared with female fetuses (P Ͻ 0.05), but these were not affected by leptin receptor antagonism (Table 4 ).
DISCUSSION
The findings of the present study demonstrate that exogenous leptin treatment and leptin receptor antagonism have differential effects on bone structure in the sheep fetus during late gestation, dependent on the bone type examined and, in some aspects, the sex of the fetus. In the femur, exogenous leptin treatment caused significant decrements in total, bone, 
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and nonbone space volumes and increments in trabecular porosity and connectivity density. In addition, compared with the saline control group, a reduction in femur midshaft diameter was observed in the male, but not female, fetuses treated with exogenous leptin. These findings show that supraphysiological concentrations of leptin impair femoral bone growth, although the trabecular bone may become a more organized and potentially stronger structure. In contrast, leptin receptor antagonism predominantly affected the developing lumbar vertebra. Leptin receptor antagonism resulted in an increase in trabecular number, DOA, and connectivity density, with less space between the structures and no change to trabecular thickness. Therefore, whereas exogenous leptin promoted growth of vertebral trabeculas, the leptin receptor antagonist caused generation and organization of the vertebral trabecular bone structure. These findings indicate that leptin normally suppresses these aspects of bone development in the axial skeleton. The responses to exogenous leptin and leptin receptor 
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antagonism occurred without any change in circulating IGF-I, osteocalcin, or other markers of bone turnover. In newborn mice, primary ossification centers in the limb bones were enlarged in size following maternal treatment with leptin during midgestation (3) . The present study is the first to investigate the consequences of direct leptin administration to the fetus for its bone structure, with potentially fewer confounding effects of leptin on maternal and placental physiology. Regional differences have been observed in the effects of leptin excess and deficiency on the appendicular and axial bones of the postnatal skeleton (19, 21) . Intracerebroventricular infusion of leptin in rats caused reductions in bone mineral content and density in the femur, but not the lumbar vertebra (19) . In ob/ob mice, the femur was reduced in length, with lower mineralization and trabecular bone volume, whereas trabecular volume and bone mineral content and density were increased in the lumbar vertebrae (21) . The bone phenotype of the leptin-deficient rodent, however, is complex, since previous studies have shown greater bone mass in both the femur and vertebrae of ob/ob and leptin receptor-deficient db/db mice (12) . Measurements of bone volume and trabecular number, thickness, and mineral density were also elevated in the femur of the leptin-deficient rat, suggesting that leptin suppresses bone formation in this species (48) . The overall effects of leptin manipulation on bone structure may depend on the balance between the peripheral stimulatory and central inhibitory control of bone turnover by leptin although the relative importance of these mechanisms, especially within specific regions of the skeleton, remains poorly understood (30) .
In the current study, the effects of exogenous leptin and leptin receptor antagonism on bone structure in the ovine fetus may be mediated by direct and/or indirect mechanisms, in particular via the hypothalamic relay. Leptin receptors are expressed on developing bone cells in fetal rodents (7, 9, 23) , and leptin stimulates proliferation of osteoblasts isolated from fetal rats in late gestation (9) . The hypothalamic control of bone development by sympathetic and CART neurones, and the role of leptin in modulating these pathways, are unknown in fetal life. In the sheep fetus during late gestation, Ob-Rb mRNA has been localized to several hypothalamic nuclei, including the arcuate nucleus and dorsomedial, ventromedial, and paraventricular regions (31) , and previous studies have shown that intracerebroventricular infusion of leptin has effects on swallowing movements and hypothalamic-pituitary-adrenal activity (25, 41) . The permeability of the blood-brain barrier to supraphysiological systemic concentrations of leptin and the leptin antagonist, however, remains to be established. The leptin mutant antagonist can bind to all forms of the leptin receptor, including the soluble Ob-Re, which enables leptin to transfer across the blood-brain barrier. The blood-brain barrier is functional in the ovine fetus from at least two-thirds of gestation although, in many regions of the brain, it is more permeable to small hydrophilic molecules in fetal compared with neonatal and adult life (44) . It is possible that the effects of the leptin receptor antagonist on vertebral bone structure in utero are largely the result of prevention of the normal inhibitory effects of leptin on bone growth via the hypothalamic relay.
Most studies using human and murine leptin receptors to examine receptor kinetics have shown that the equilibrium dissociation constant (K d ) is in the subnanomolar range; K d values are reported to range from 0.1 to 15 nM for leptin receptors in solution and 0.2-2.6 nM for those attached to the cell surface, with variation between studies possibly dependent on the techniques and cell types used (38) . The mean plasma concentration of leptin in the saline-infused control fetuses at 130 days of gestation was 0.04 nM in the present study and rises to 0.06 nM in sheep fetuses near term (35) . In the fetuses infused with recombinant leptin, the mean plasma leptin concentrations were 0.29 and 0.51 nM on the fifth day of infusion of the two leptin doses (LEP1 and LEP2). Therefore, although plasma leptin concentrations achieved in the infused fetuses were significantly above the normal endogenous levels, they were still within the range of the leptin receptor K d .
It is also possible that exposure to supraphysiological concentrations of leptin may modify tissue expression of the leptin receptor and the activity of downstream signaling pathways. In a previous study examining the effect of leptin treatment on lung structure and function in fetal sheep, the 5-day infusion of the lower LEP1 dose caused a significant increase in pulmonary leptin receptor mRNA abundance (10) . The expression and activity of leptin receptors in the bone and hypothalamus were not investigated in the present study although it has been shown that long-term exposure to leptin in obese adult animals and human subjects leads to leptin insensitivity in the appetite networks of the hypothalamus (32) .
In the present study, sexual dimorphism was evident in a variety of bone measurements, and male fetuses appeared to be more sensitive to the actions of exogenous leptin and leptin receptor antagonism than female fetuses. The mechanisms responsible, and the consequences for bone structure and mechanical strength in later life, remain to be determined. Different patterns in circulating testosterone concentration have been reported in male and female sheep fetuses from midgestation (40) , and there may be sex-specific expression of endocrine and other signaling pathways in developing bone. Treatment of pregnant rats with leptin in midgestation led to a lower birth weight and greater longer-term reductions in skeletal growth and bone mineral content in male compared with female offspring (33) . It is possible that a longer duration of exposure to exogenous leptin and leptin receptor antagonism, and/or at different time points in bone development, would have led to more profound effects on the developing ovine skeleton in both sexes. In postnatal life, leptin is known to have an important role in the physiological adaptations to fasting: low circulating levels of leptin, because of reductions in body fat mass, lead to enhanced appetite and impaired fertility and body, including bone, growth (20) . In mice, leptin treatment has been shown to correct the reduction in tibial bone length induced by calorie restriction, independent of IGF-I levels (16) . In addition, the effects of calorie restriction on bone formation are bone site-specific, with bone mineral content decreased in the femur and increased in the vertebra of mice undernourished over a 6-mo period (5) . Before birth, the role of leptin in the response to changes in nutrient availability is less clear. In the sheep fetus, maternal undernutrition appears to have little effect on leptin production although adipose leptin mRNA abundance and plasma leptin concentration are sensitive to levels of glucose, insulin, oxygen, and glucocorticoids in utero (14) .
Perspectives and Significance
This study has shown a role for leptin in the growth and development of the ovine fetal skeleton that is dependent on the leptin concentration, bone site, and sex of the fetus. Further longer-term studies are required to determine the extent to which physiological changes in leptin contribute to the endocrine control of bone growth during normal and suboptimal nutrition in utero. In addition, it will be important to assess whether the changes observed in bone structure induced by variations in leptin activity before birth have consequences for bone function across the life course. 
